drugset / Trial / NCT00467012
Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To investigate the efficacy, safety, and pharmacokinetics when R435 and paclitaxel are administered concomitantly to patients with metastatic breast cancer.
Timeline
- Start
- 2007-04
- Primary completion
- 2009-06
- Completion
- 2011-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | — |
| Subject | Paclitaxel | Small molecule | 90 mg/m2 | — |